SCHEDULE: Alyeska Investment Group Amends 9.35% Immunic Stake

Alyeska Investment Group, L.P. and its affiliates filed an amendment disclosing a 9.35% beneficial ownership stake in Immunic, Inc., comprising 11,250,000 shares.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 11,250,000 shares of Immunic, Inc. Common Stock.
• This ownership represents 9.35% of Immunic, Inc.'s outstanding common stock.
• The reported stake includes 7,500,000 warrants and 3,750,000 pre-funded warrants.
• The percentage calculation is based on 120,284,724 outstanding common shares, as reported in Immunic, Inc.'s Form 10-Q filed with the SEC on November 13, 2025.
• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Immunic, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a significant stake by an institutional investor like Alyeska Investment Group can be viewed as a moderately positive signal of confidence in Immunic, Inc. However, the filing explicitly states the stake is for ordinary course business and not for influencing control, which maintains a neutral stance on any activist intent.

Positives

• The disclosure of a significant beneficial ownership stake (9.35%) by a prominent institutional investor like Alyeska Investment Group can be interpreted as a positive signal of confidence in Immunic, Inc.'s long-term prospects.

Risks

• The reporting persons explicitly stated that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Immunic, Inc., mitigating immediate control-related risks from this specific filing.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding Immunic, Inc.'s future operations or financial performance.

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor and does not inherently provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence trading activity.

Key Dates

Keywords

Immunic Inc, Alyeska Investment Group, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Equity Stake